Inari Medical Announces Impressive Results from ClotTriever CLOUT Registry; Shows Significantly Lower Rates of Post Thrombotic Syndrome than Historical Deep Vein Thrombosis Trials
Inari Medical, a global leader in medical technology, recently announced the interim two-year results from its ClotTriever CLOUT Registry. The results revealed that the rates of Post Thrombotic Syndrome (PTS) observed at two years were not only excellent but also significantly lower when compared to rates reported in historical Deep Vein Thrombosis (DVT) trials.
PTS is a potentially debilitating condition that occurs in patients who have previously experienced DVT. It is characterized by the development of chronic leg pain, swelling, skin discoloration, and ulcers in the affected area. Historically, the rates of PTS have been a cause of concern, with patients experiencing long-term complications and diminished quality of life.
The ClotTriever CLOUT Registry is an ongoing, multicenter, observational study that aims to evaluate the real-world outcomes of patients treated with Inari’s ClotTriever System, a minimally invasive device designed to remove large blood clots from veins. The interim results from the registry have now demonstrated the effectiveness of this innovative technology in preventing the incidence of PTS.
The study enrolled a total of 640 patients across 32 sites. The observed rates of PTS at two years were found to be excellent, with only a minimal percentage of patients experiencing the condition. These rates were significantly lower when compared to historical DVT trials, indicating a major breakthrough in the treatment of DVT and its associated complications.
Dr. Maria Rodriguez, a leading vascular surgeon and one of the principal investigators for the ClotTriever CLOUT Registry, expressed her excitement over these results. She stated, The low rates of PTS observed in the registry are a game-changer for patients suffering from DVT. We have never seen such positive outcomes in terms of preventing this debilitating condition.
In addition to the remarkable clinical achievements, Inari Medical also experienced substantial growth in revenue during the corresponding time period. Recording a year-on-year increase of 30.86%, the company has showcased its robust financial performance. Sequentially, revenue also grew by 5.78%.The positive financial results reflect the company’s solid market position and the rising demand for its innovative medical technologies. Inari Medical’s corporate clients have been instrumental in driving its revenue growth, indicating strong partnerships and customer satisfaction.
Overall, Inari Medical’s latest announcement has attracted considerable attention in the medical community. The remarkable two-year results from the ClotTriever CLOUT Registry, showing significantly lower rates of PTS compared to historical DVT trials, highlight the potential of Inari’s ClotTriever System in transforming the treatment landscape for DVT patients.
Heading: Inari Medical’s Revolutionary ClotTriever System Delivers Unprecedented Results, Significantly Minimizing Post Thrombotic Syndrome Rates
Comments